Background: The present study was conducted to compare the Efficacy of MgSO4 and Nifedipine in Pre- Term Labour.

Materials & Methods: The present study was conducted on 70 patients in active preterm labor who were 24 weeks to 33 weeks and 6 days gestation. Patients were divided into 2 groups. Group I patients received Magnesium Sulfate and group II patients received Nifedipine. In Both Groups, Primary outcome and Secondary outcome was recorded. Adverse effects were also recorded.

Results: There were no differences between the groups in the proportion of patients who delivered within 48 hours, Gestational age at delivery and delivery before 37 weeks (P< 0.05). The mean birth weight of babies in group I was 2510 grams and in group II was 2630 grams, Respiratory Distress Syndrome (RDS) was seen in 8 in group I and 7 in group II, Intraventricular Hemorrhage (IVH) was seen in 1 in group I only and Necrotizing Enterocolitis (NEC) was not seen in any group, sepsis was seen in 2 in Group I and 1 in Group II, death 1 in group I only. Neonatal Intensive Care Unit admission (NICU) was seen in 18 in group I and 13 in group II and mean days in NICU was 8.2 days in Group I and 4.1 days in Group II. 

Conclusion: Authors found that more patients in Group I achieved the Primary outcome of prevention of Preterm delivery for 48 hours with uterine quiescence as compared to Group II. Nifedipine was associated with fewer maternal adverse effects as compared to Magnesium Sulphate.

Keywords: Magnesium sulphate, Nifedipine, Pre term labour

1. Ananth CV, Joseph KS, Oyelese Y, Demissie K, Vintzileos AM. Trends in preterm birth and perinatal mortality among singletons: United States, 1989 through 2000. Obstet Gynecol 2005;105: 1084–91.
2. Behrman RE, Butler AS, editors. Preterm birth: causes, consequences, and prevention. Washington (DC): National Academies Press; 2007; 398.
3. Norwitz ER, Robinson JN, Challis JR. The control of labor. N Engl J Med 1999;341:660–6. 5. Lewis DF. Magnesium sulfate: the first-line tocolytic. Obstet Gynecol Clin North Am 2005;32:485–500.
4. Crowther CA, Brown J, McKinlay CJ, Middleton P. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev. 2014(8):CD001060.
5. Grimes DA, Nanda K. Magnesium sulfate tocolysis: time to quit. Obstet Gynecol 2006;108:986–9.
6. Glock JL, Morales WJ. Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: A randomized study. Am J Obstet Gynecol 1993;169:960–4.
7. Haghighi L. Prevention of preterm delivery: nifedipine or magnesium sulfate. Int J Gynaecol Obstet 1999;66:297–8.
8. Khooshideh M, Rahmati J, Teimoori B. Nifedipine versus magnesium sulfate for treatment of preterm labor: Comparison of efficacy and adverse effects in a randomized controlled trial. Shiraz E-Medical Journal. 2017 Jun;18(6).
9. Lyell DJ, Pullen K, Campbell L, Ching S, Druzin ML, Chitkara U, Burrs D, Caughey AB, El-Sayed YY. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor: a randomized controlled trial. Obstetrics & Gynecology. 2007 Jul 1;110(1):61-7.
10. Herschel M, Mittendorf R. Tocolytic magnesium sulfate toxicity and unexpected neonatal death. J Perinatol 2001; 21: 261–2.
11. Malaeb SN, Rassi AI, Haddad MC, Seoud MA, Yunis A. Bone mineralization in newborns whose mothers received magnesium sulphate for tocolysis of premature labour. Pediatr Radiol 2004;34:384–6.
12. Berkman ND, Thorp JM Jr, Lohr KN, Carey TS, Hartmann KE, Gavin NI, et al. Tocolytic treatment for the management of preterm labor: A review of the evidence. Am J Obstet Gynecol 2003;188:1648–59.

Dr Shaesta Iqbal

PGT 3rd year Department of obstetrics & Gynaecology, KMCH